Cantor Fitzgerald Maintains Overweight on Prothena Corp, Raises Price Target to $103
Cantor Fitzgerald analyst Charles Duncan maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and raises the price target from $70 to $103.
Expert Ratings For Prothena Corp
Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the following analyst ratings:
Oppenheimer Maintains Outperform on Prothena Corp, Raises Price Target to $90
Oppenheimer analyst Jay Olson maintains Prothena Corp (NASDAQ:PRTA) with a Outperform and raises the price target from $82 to $90.
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
Return on Capital Employed Insights for Prothena Corp
According to Benzinga Pro, during Q2, Prothena Corp (NASDAQ:PRTA) earned $27.95 million, a 187.04% increase from the preceding quarter. Prothena Corp also posted a total of $60.07 million in sales, a 37444.38% increase since Q1.
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)
Stocks That Hit 52-Week Highs On Thursday
Before 10 a.m. ET on Thursday, 91 companies hit new 52-week highs.
What 9 Analyst Ratings Have To Say About Prothena Corp
Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA) within the last quarter:
Last 30 Days
1 Month Ago
2 Months Ago
10 Biggest Price Target Changes For Monday
Jefferies raised the price target on Tesla, Inc. (NASDAQ: TSLA) from $700 to $850.. Tesla shares rose 1.5% to $709.51 in pre-market trading.